摘要:
A process for the production of 4-(heteroaryl-methyl)-halogen-1(2H)-phthalazinones, especially 4-(4-pyridylmethyl)-1(2H)-phthalazinone, is described, which is characterized by the reaction of phthalidyl-3-triphenylphosphonium salt with 4-pyridine aldehyde in the presence of a basic adjuvant, subsequent reaction with hydrazine hydrate and subsequent acid treatment, whereby this process avoids the technical safety and environmental problems of the known processes.
摘要:
The present invention provides a compound having a steroid C17,20-lyase inhibitory activity, which is useful as a prophylactic or therapeutic agent of prostatism and tumor such as breast cancer and the like. A compound represented by the formula: 1 wherein R is a hydrogen atom or a protecting group, R1 is a lower alkyl group or a cyclic alkyl group, and ring A and ring B are each an optionally substituted 5-membered or 6-membered ring having an amide bond in the ring, or a salt thereof.
摘要:
A compound of formula: 1 or an isomer, salt, solvate, chemically protected form, or prodrug thereof, wherein A and B together represent an optionally substituted, fused aromatic ring; RL is a C5-7 aryl group substituted in the meta position by the group R2, and optionally further substituted; wherein R2 is selected from: 2 and its use as a pharmaceutical, in particular for the treatment of diseases ameliorated by inhibiting the activity of PARP.
摘要翻译:下式化合物或其异构体,盐,溶剂合物,化学保护形式或前药,其中A和B一起表示任选取代的稠合芳环; R L是由R 2基团在间位取代的任选进一步取代的C 5-7芳基; 其中R 2选自:及其作为药物的用途,特别是用于治疗通过抑制PARP的活性而改善的疾病。
摘要:
The invention relates to the use of inhibitors of the microsomal triglyceride transfer protein (MTP) for reducing the number of postprandial triglyceride-rich lipoprotein particles (ppTRL) or for reducing their decomposition products i.e. the cholestcrol-rich nullsmall remnant particlenull (remnants). Said particles are associated with apolipoprotein B-48 (ApoB-48) and are designated as nullppTRLnull in the further course of events.
摘要:
The invention concerns compounds of formula (I): R-A-Rnull wherein: A is as defined in the description; R represent a group (V), (VI), (VII), or (VIII), where E, Q, R1, R2, R3, v and R4 are as defined in the description; Rnull represents a null(CH2)tnullR5 group wherein t and R5 are as defined in the description, and medicaments containing the same. 1
摘要:
The invention provides compounds of the formula 1 and methods of using those compounds for treating a disease or condition in a mammal wherein a 5-HT receptor, such as a 5-HT6 receptor, is implicated and modulation of a 5-HT function is desired, wherein A, G and W1-W6 are defined as herein.
摘要:
The present invention provides a compound of formula I 1 which is useful as antiviral agents, in particular, as agents against viruses of the herpes family.
摘要:
Described are compositions comprising a muscarinic receptor antagonist and an N-acylated heterocycle derivative having affinity for serotonergic receptors, and enantiomers, diastereoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts thereof. The combination of a muscarinic receptor antagonist and an N-acylated heterocycle, or an enantiomer, diastereoisomer, N-oxide, polymorph, solvate or pharmaceutically acceptable salt thereof, is useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT1A receptors.
摘要:
Compounds, compositions containing compounds, methods of sing compounds, and processes of making compounds, of formula I containing at least one ring nitrogen: 1 or a pharmaceutically acceptable base or acid addition salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein: X is double-bonded oxygen or nullOH; when R7 is present, it is hydrogen or lower alkyl; Y represents the atoms necessary to form a fused mono-, bi- or tricyclic, carbocyclic or heterocyclic ring, wherein each individual ring has 5-6 ring member atoms; and Z is (i) nullCHR2CHR3null wherein R2 and R3 are independently hydrogen, alkyl, aryl, or aralkyl; (ii) nullR6CnullCR3null wherein R3 and R6 are independently hydrogen, lower alkyl, aryl, aralkyl, halo, nullNO2, nullCOOR7, or nullNR7R8 where R8 is independently hydrogen or C1-C9 alkyl, or R6 and R3, taken together, form a fused aromatic ring, wherein each individual ring has 5-6 ring members; (iii) nullR2CnullNnull; (iv) nullCR2(OH)nullNR7null; or (v) nullC(O)nullNR7null.
摘要:
This invention relates generally to nitrogen containing heterobicycles of formulas A and B: 1 which are inhibitors of trypsin-like serine protease enzymes, especially factor Xa, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.